Active Stock Momentum: Johnson & Johnson (JNJ)

53
u.s stocks

Johnson & Johnson (NYSE:JNJ) Belonging to the Medical sector which surged 0.73% and closed its last trading session at $118.13.

The company reported its last EPS on 6/30/2016 and is expected to report its next EPS on 10/18/2016. Currently, the stock has a 1 Year Price Target of $126.61.

The consensus recommendation, according to Zacks Investment research, is 2.11. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. The Stock had a 2.22 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 2.26 and 2.22 respectively.

Johnson & Johnson on 6/30/2016 reported its EPS as $1.74 with the analysts projecting the EPS of the stock as $1.68. The company beat the analyst EPS Estimate with the difference of $0.06. This shows a surprise factor of 3.6%.

Many analysts have provided their estimated foresights on Johnson & Johnson Earnings, with 19 analysts believing the company would generate an Average Estimate of $1.65. Whereas they predicted High and Low Earnings Estimate as $1.75 and $1.59 respectively. While in the same Quarter Previous year, the Actual EPS was $1.49.

Analysts are also projecting an Average Revenue Estimate for Johnson & Johnson as $17.7 Billion in the Current Quarter. This estimate is provided by 17 analysts. The High Revenue estimate is predicted as 17.98 Billion, while the Low Revenue Estimate prediction stands at 17.52 Billion. The company’s last year sales total was 17.1 Billion.

For the Current Quarter, the growth estimate for Johnson & Johnson is 10.7%, while for the Next Quarter the stock growth estimate is 9.7%. In the past 5 years, the stock showed growth of 6.33% per annum. While for the next 5 years, the growth estimate is 6.52%.

The Company got Initiated by Standpoint Research on 20-May-16 to Sell.

Insider Trades for Johnson & Johnson show that the latest trade was made on 25 Jul 2016 where Caruso (Dominic J), the Chief Financial Officer completed a transaction type “Sell” in which 41146 shares were traded at a price of $125.01.

Over the period of 6 months, Insider Purchases show a total of 2 transaction in which 5000 shares were traded.

18 analysts projected Price Targets for Johnson & Johnson. The analysts believe that the company stock price could grow as high as $142. The Low Price target projection by analysts is $105 and the Mean Price Target is $126.61.

Johnson & Johnson (NYSE:JNJ) has the market capitalization of $324.31 Billion. The company rocked its 52-Week High of $126.07 on Jul 20, 2016 and touched its 52-Week Low of $92.58 on Oct 6, 2015. The stock has Return on Assets (ROA) of 11.1 percent. Return on Equity (ROE) stands at 20.9% and Return on Investment (ROI) of 14.7 percent.

The stock is currently showing YTD performance of 17.44 Percent. The company has Beta Value of 0.64 and ATR value of 1.16. The Weekly and Monthly Volatility stands at 1.15% and 0.92%.

Company profile:

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and women’s health fields, nutritional and over-the-counter pharmaceutical products. The company’s Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and women’s health products. Johnson & Johnson is based in New Brunswick, New Jersey.